{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:39:37Z","timestamp":1792528777247,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"DOI":"10.1186\/s13561-026-00824-x","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:24:06Z","timestamp":1784849046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Binliang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"824_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available at: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/20-breast-fact-sheet.pdf. Accessed January 28, 2026."},{"key":"824_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8:95. https:\/\/doi.org\/10.1038\/s41523-022-00468-0.","journal-title":"NPJ Breast Cancer"},{"key":"824_CR3","unstructured":"National Cancer Institute. Cancer stat facts: female breast cancer subtypes. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed January 28, 2026."},{"key":"824_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(20)32531-9.","journal-title":"Lancet"},{"key":"824_CR5","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer, Version 1.2026. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed January 16, 2026."},{"key":"824_CR6","doi-asserted-by":"publisher","unstructured":"Punie K, Kurian AW, Ntalla I, Sjekloca N, Estrin A, Dabrowski EC, Lai C, Hurvitz S. Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States. Oncologist. 2025;30. https:\/\/doi.org\/10.1093\/oncolo\/oyaf034.","DOI":"10.1093\/oncolo\/oyaf034"},{"key":"824_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/fon-2020-1021","volume":"17","author":"KE Skinner","year":"2021","unstructured":"Skinner KE, Haiderali A, Huang M, Schwartzberg LS. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer. Future Oncol. 2021;17:931\u201341. https:\/\/doi.org\/10.2217\/fon-2020-1021.","journal-title":"Future Oncol"},{"key":"824_CR8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","volume":"25","author":"A Zippelius","year":"2025","unstructured":"Zippelius A, Tolaney SM, Tarantino P, Balthasar JP, Thurber GM. Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment. Nat Rev Cancer. 2025;25:925\u201344. https:\/\/doi.org\/10.1038\/s41568-025-00869-w.","journal-title":"Nat Rev Cancer"},{"key":"824_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023;129:283\u201395. https:\/\/doi.org\/10.1002\/cncr.34507.","journal-title":"Cancer"},{"key":"824_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med. 2026;394:354\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2508959.","journal-title":"N Engl J Med"},{"key":"824_CR11","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975. https:\/\/doi.org\/10.1136\/bmj-2021-067975.","journal-title":"BMJ"},{"key":"824_CR12","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1200\/jco.2000.18.12.2385","volume":"18","author":"B Norris","year":"2000","unstructured":"Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic\/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol. 2000;18:2385\u201394. https:\/\/doi.org\/10.1200\/jco.2000.18.12.2385.","journal-title":"J Clin Oncol"},{"key":"824_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.breast.2022.10.010","volume":"66","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Liu K, Wang M, Wang K, Zhu H. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: a cost-effectiveness analysis. Breast. 2022;66:191\u20138. https:\/\/doi.org\/10.1016\/j.breast.2022.10.010.","journal-title":"Breast"},{"key":"824_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14737167.2016.1222907","volume":"16","author":"N Paracha","year":"2016","unstructured":"Paracha N, Thuresson PO, Moreno SG, MacGilchrist KS. Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;16:549\u201359. https:\/\/doi.org\/10.1080\/14737167.2016.1222907.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"824_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","volume":"68","author":"Y Lang","year":"2023","unstructured":"Lang Y, Chai Q, Tao W, Liao Y, Liu X, Wu B. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer. Breast. 2023;68:173\u201380. https:\/\/doi.org\/10.1016\/j.breast.2023.02.003.","journal-title":"Breast"},{"key":"824_CR16","unstructured":"Centers for Medicare & Medicaid Services. Drug Average Sales Price. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files. Accessed December 19, 2025."},{"key":"824_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"824_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12874-022-01567-z","volume":"22","author":"JJ Zhao","year":"2022","unstructured":"Zhao JJ, Syn NL, Tan BKJ, Yap DWT, Teo CB, Chan YH, et al. KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. BMC Med Res Methodol. 2022;22:93. https:\/\/doi.org\/10.1186\/s12874-022-01567-z.","journal-title":"BMC Med Res Methodol"},{"key":"824_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lungcan.2020.05.011","volume":"146","author":"J Han","year":"2020","unstructured":"Han J, Tian K, Yang J, Gong Y. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: an updated PACIFIC trial-based cost-effectiveness analysis. Lung Cancer. 2020;146:42\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.011.","journal-title":"Lung Cancer"},{"key":"824_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/jco.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41:22\u201331. https:\/\/doi.org\/10.1200\/jco.22.01643.","journal-title":"J Clin Oncol"},{"key":"824_CR21","doi-asserted-by":"publisher","unstructured":"Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, G\u00f6ger YE, Rausch S, Kang SH, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2511674.","DOI":"10.1056\/NEJMoa2511674"},{"key":"824_CR22","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1038\/s41591-025-03883-5","volume":"31","author":"S Hong","year":"2025","unstructured":"Hong S, Wang Q, Cheng Y, Luo Y, Qu X, Zhu H, et al. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med. 2025;31:3654\u201361. https:\/\/doi.org\/10.1038\/s41591-025-03883-5.","journal-title":"Nat Med"},{"key":"824_CR23","doi-asserted-by":"publisher","first-page":"102847","DOI":"10.1016\/j.ctrv.2024.102847","volume":"131","author":"G Villacampa","year":"2024","unstructured":"Villacampa G, Cresta Morgado P, Carit\u00e0 L, Navarro V, Pascual T, Dienstmann R. Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: a systematic review and meta-analysis. Cancer Treat Rev. 2024;131:102847. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102847.","journal-title":"Cancer Treat Rev"},{"key":"824_CR24","doi-asserted-by":"publisher","first-page":"734594","DOI":"10.3389\/fonc.2021.734594","volume":"11","author":"J Chen","year":"2021","unstructured":"Chen J, Han M, Liu A, Shi B. Economic evaluation of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer in China and the US. Front Oncol. 2021;11:734594. https:\/\/doi.org\/10.3389\/fonc.2021.734594.","journal-title":"Front Oncol"},{"key":"824_CR25","doi-asserted-by":"publisher","unstructured":"Wang SY, Tai YS, Leung HWC, Leung SH, Chan ALF. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer in Taiwan. Cancers (Basel). 2025;17. https:\/\/doi.org\/10.3390\/cancers17203305.","DOI":"10.3390\/cancers17203305"},{"key":"824_CR26","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2217\/imt-2022-0082","volume":"14","author":"M Huang","year":"2022","unstructured":"Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, et al. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. Immunotherapy. 2022;14:1027\u201341. https:\/\/doi.org\/10.2217\/imt-2022-0082.","journal-title":"Immunotherapy"},{"key":"824_CR27","doi-asserted-by":"publisher","first-page":"1654177","DOI":"10.3389\/fphar.2025.1654177","volume":"16","author":"Y Hou","year":"2025","unstructured":"Hou Y, Yang S, Wang X, Zhao S, Liu H, Kang S. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in China. Front Pharmacol. 2025;16:1654177. https:\/\/doi.org\/10.3389\/fphar.2025.1654177.","journal-title":"Front Pharmacol"},{"key":"824_CR28","doi-asserted-by":"publisher","first-page":"175883592095019","DOI":"10.1177\/1758835920950199","volume":"12","author":"Y Su","year":"2020","unstructured":"Su Y, Fu J, Du J, Wu B. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. Ther Adv Med Oncol. 2020;12:1758835920950199. https:\/\/doi.org\/10.1177\/1758835920950199.","journal-title":"Ther Adv Med Oncol"},{"key":"824_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","volume":"5","author":"S Gnjatic","year":"2017","unstructured":"Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017;5:44. https:\/\/doi.org\/10.1186\/s40425-017-0243-4.","journal-title":"J Immunother Cancer"},{"key":"824_CR30","doi-asserted-by":"crossref","unstructured":"Garassino MC, et al. Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is predictive of Clinical Outcomes in TROPION-Lung 01. 2024 WCLC. PL02.11.","DOI":"10.1016\/j.jtho.2024.09.015"},{"key":"824_CR31","unstructured":"Yi-Long Wu, et al. Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced\/metastatic non-small cell lung cancer (a\/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02. 2025 ELCC.\u00a0357P."}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00824-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00824-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00824-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:03:05Z","timestamp":1792526585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00824-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00824-x","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors; it does not require the approval of the independent ethics committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"120"}}